Blood Podcast
የቻናል ዝርዝሮች
Blood Podcast
The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.
የቅርብ ጊዜ ክፍሎች
347 ክፍሎች
Busulfan-melphalan conditioning in newly diagnosed, transplant-eligible multiple myeloma; and use of spatial transcriptomics to probe the three-dimensional properties of multiple myeloma bone marrow microenvironments
In this week's episode we’ll learn more about a study comparing busulfan-melphalan with melphalan alone as the conditioning protocol for newly diagnos...
How I Treat Wiskott-Alrich syndrome
In this How I Treat podcast episode, Laura Michaelis, MD interviews Sung-Yun Pai, MD about their recently published article in Blood journal "How I tr...
Use of Marstacimab for Prophylaxis in hemophilia A and B; matched-donor allogeneic CD19 CAR-T in adult B-ALL; a new prognostic index for T-cell cutaneous lymphomas
In this week's episode we'll learn about targeting the tissue factor pathway inhibitor with a monoclonal antibody to rebalance HEMOSTASIS in hemophili...
Epstein-Barr virus genomic variants in human disease states, somatic GATA1 mutations and leukemia in Down syndrome, and new definitions for high-risk multiple myeloma
In this week's episode, we’ll learn more about relationships between Epstein-Barr virus genomic variants and human diseases, including hematological m...
Review Series on Acute Lymphoblastic Leukemia (ALL)
In this Review Series episode, Associate Editor Dr. Hervé Dombret speaks with Dr. Mark Litzow about the latest immunotherapy advances for Acute Lympho...
Azacitidine holds promise in VEXAS syndrome; a step forward in precision blood matching; identifying a new vulnerability in TP53-mutated AML
In this week's episode we'll learn about Azacitidine in VEXAS syndrome. Treatment can provide responses in patients with this complex autoinflammatory...
Diffuse large B-cell lymphoma’s long-term effects on immune profiles, plasminogen activation and prevention of venous thromboembolism, and PARP inhibitors in hematological malignancies carrying epigenetic mutations
In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and o...
“Ironing out” Tet2-mutant HSPCs; A CAR-T “license to kill” in T cell leukemia/lymphoma; insights on cHL genetics, through the lens of ctDNA
In this week's episode, we'll learn about how TET2 is often mutated in myeloid malignancies and clonal hematopoiesis. In new work, expansion of Tet2-m...
Targeting NPM1 in AML with a menin inhibitor; in primates, a CD137 ADC eliminates acute GVHD
In this week's episode we'll learn about targeting NPM1 in acute myeloid leukemia. Researchers report the first clinical evidence of a menin inhibitor...
How I Treat Series on Iron Overload in Hematologic Disorders
Blood Editor, Dr. Thomas Coates interviews Dr. Emanuele Angelucci on his paper, "How I manage iron overload in the hematopoietic cell transplantation...
Early prediction of follicular lymphoma patients with poor survival; immune hotspots in aplastic anemia; role of allo-transplant for Hodgkin lymphoma in the checkpoint inhibitor era
In this week's episode we'll learn about how by combining PET response with circulating tumor DNA, or ctDNA, in newly treated patients with follicula...
Exogenous CD19 stimulation in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy, sequential rapid immune-assay in heparin-induced thrombocytopenia diagnosis, and new survival prediction models for chronic myelomonocytic leukemia
In this week's episode, we’ll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia tr...
How I Treat series on Acute Myeloid Leukemia
In this episode, Associate Blood editor Dr. Selina Luger leads a discussion with Drs. Courtney DiNardo, Eunice Wang, Andrew Wei and Gail Roboz about t...
Daratumumab maintenance in newly-diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in myeloproliferative neoplasms; and novel genetic loci associated with the risk of heavy menstrual bleeding
In this week's episode, we’ll learn more about the effects of daratumumab maintenance on minimal residual disease in patients with newly diagnosed, tr...
Hematopoietic stem cells with enhanced transplantability, ruxolitinib for refractory macrophage activation syndrome, and magrolimab in newly diagnosed acute myeloid leukemia
In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with ad...
A JAK inhibitor for CRS and ICANS prevention; ChAdOx1-platelet interactions and post-vaccination arterial thrombosis; lineage switch, an emerging mechanism of leukemia relapse
In this week's episode, we'll learn about a JAK inhibitor to prevent complications of CD19-directed CAR T-cell therapy. In a phase 2 study, itacitinib...
Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with low von Willebrand factor
In this week's episode we’ll learn more about the use of ruxolitinib plus dexamethasone to treat newly diagnosed patients with adult hemophagocytic ly...
Review series on mantle cell lymphoma
In this episode, Associate Editor Dr. Philippe Armand discusses the Review Series on mantle cell lymphoma with author Dr. Christine Ryan. Both were au...
Rapid, high-sensitivity ADAMTS13 assays for TTP; combination CD38/PD-1 blockade in extranodal NK/T-cell lymphoma; a “zombie enzyme” in CREBBP-mutant lymphomas
In this week's episode, we'll learn about rapid, high-sensitivity diagnostic assays for TTP, or thrombotic thrombocytopenic purpura, that can reduce u...
A novel mouse model of sickle cell SC disease; multiple myeloma induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone; and splicing factor mutations in myelodysplastic syndromes
In this week's episode we’ll learn more about a novel mouse model that recapitulates many of the properties of human sickle cell SC disease; results f...
An AI model for transplant risk in myelofibrosis; preventing priapism in men with sickle cell anemia; hallmarks of T cell exhaustion absent in newly diagnosed MM
In this week's episode, we'll learn about using AI to assess transplant risk in myelofibrosis. In a step toward personalized medicine, researchers rep...
Social determinants of health and access to allogeneic hematopoietic cell transplantation, megakaryocyte growth factor receptor-based pretransplant conditioning for ex vivo autologous gene therapy, and novel protein biomarkers for risk stratification in a
In this week's episode, we’ll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in pa...
Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets
Blood editor Dr. Laurie Sehn discusses the topic of "Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets" featuring Drs. Mark Ros...
A key role for T-cell TET3 in chronic GVHD; a BTK inhibitor for ITP; co-inhibition of pre-TCR and IL-7R pathways in a T-ALL patient subset
In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immuno...
Special Episode: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
In this special episode, Dr. Shaji Kumar from the Mayo Clinic speaks with Blood editor Dr. Laurie Sehn on a paper recently published in Blood, "Elimin...
How I Treat Series on Geriatric Hematology
In this How I Treat Series episode Dr. Thomas Ortel leads a discussion with author Dr. Patrick Foy on his paper “How I diagnose and treat thrombocytop...
Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance
In this week's episode, we’ll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics...
New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE
In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master tra...
How I Treat Transfusion Medicine (part 2)
In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie...
Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma
In this week's episode we’ll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune mi...
How I Treat Transfusion Medicine (part 1)
In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on...
Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT
In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remissio...
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease
In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenan...
Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature
In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first...
Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell cardiomyopathy
In this week's episode we’ll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene...
How I Treat Myeloproliferative Neoplasms
In this How I Treat series episode Blood Associate Editor, Dr. Jason Gotlib speaks with Drs. Aaron Gerds, Andreas Reiter, and Claire Harrison. The con...
The decline of transplant for relapsed myeloma; DDAVP response in bleeding disorders; dual DOT1L/EZH2 targeting in DLBCL
In this week's episode we'll learn about the role of autologous transplant for relapsed myeloma. In an updated analysis of the GMMG ReLApsE trial, sal...
Interleukin-1 signaling pathways in myelodysplastic syndromes, the immune checkpoint regulator VISTA as a target in graft-vs-host disease, and epcoritamab plus chemotherapy in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma
In this week's episode we’ll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic...
Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL
In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function...
Blood Bonus Episode: What is a Blood group?
In this bonus episode of the Blood podcast, we'll hear from Dr. Nicole Thornton, senior author of the article “Deletions in the MAL gene result in los...